Evidence map›Paper›PMID 38390384›Full record

ArticleFrontiers in transplantation2022

Progress in islet xenotransplantation: Immunologic barriers, advances in gene editing, and tolerance induction strategies for xenogeneic islets in pig-to-primate transplantation.

Daniel L Eisenson, Yu Hisadome, Michelle R Santillan, Kazuhiko Yamada

Open access · diamondAbstract read
In one paragraph

Article in Frontiers in transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Cell Therapy for T1D Beyond BLA: Gearing Up Toward Clinical Practice.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Daniel L EisensonDepartment of Surgery, The Johns Hopkins Hospital, Baltimore, MD, United States.
Yu HisadomeDepartment of Surgery, The Johns Hopkins Hospital, Baltimore, MD, United States.
Michelle R SantillanDepartment of Surgery, The Johns Hopkins Hospital, Baltimore, MD, United States.
Kazuhiko YamadaDepartment of Surgery, The Johns Hopkins Hospital, Baltimore, MD, United States.
Johns Hopkins Hospital · US

Funding

Composite porcine islet-kidney xenotransplants to cure diabetes and renal failureU01AI152881 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SACHS, DAVID H, YAMADA, KAZUHIKO · 2020 to 2024
$6.3M
NIAID NIH HHS U01 AI152881
6 · The paper itself

Abstract

Islet transplantation has emerged as a curative therapy for diabetes in select patients but remains rare due to shortage of suitable donor pancreases. Islet transplantation using porcine islets has long been proposed as a solution to this organ shortage. There have already been several small clinical trials using porcine islets in humans, but results have been mixed and further trials limited by calls for more rigorous pre-clinical data. Recent progress in heart and kidney xenograft transplant, including three studies of pig-to-human xenograft transplant, have recaptured popular imagination and renewed interest in clinical islet xenotransplantation. This review outlines immunologic barriers to islet transplantation, summarizes current strategies to overcome these barriers with a particular focus on approaches to induce tolerance, and describes an innovative strategy for treatment of diabetic nephropathy with composite islet-kidney transplantation.

Indexed as

composite islet-kidneyislet transplantationporcine islet xenotransplantationtransplantation tolerancexenotransplantation

Identifiers

PMID38390384
PMCPMC10883655
OpenAlexW4327799693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.